| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/30/2003 | US20030023993 Nucleotide sequences coding polypeptide for use in the treatment of necrosis, septic shock and inflammation |
| 01/30/2003 | US20030023990 Jnk3 modulators and methods of use |
| 01/30/2003 | US20030023337 Manufacturing method |
| 01/30/2003 | US20030023209 Scar reduction |
| 01/30/2003 | US20030023117 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| 01/30/2003 | US20030023104 For prolonging or altering the activity of a compound which is a member of the chlorambucil family |
| 01/30/2003 | US20030023100 For therapy of inflammatory and allergic reactions, drug or alcohol abuse, diarrhoea, gastritis, ulcers, cardiovascular diseases, urinary incontinence, depressions, states of shock, migranes, narcolepsy, overweight, asthma, glaucoma, etc. |
| 01/30/2003 | US20030023098 Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| 01/30/2003 | US20030023096 Useful as anti-hyperlipemia, for the prevention of abortion, for analgesics, as antidiarrheals, sleep inducer, diuretic, anti-diabetes, abortient, cathartics, antiulcer, anti-gastritis or antihypertensive etc. |
| 01/30/2003 | US20030023093 For use as antitumor agents |
| 01/30/2003 | US20030023092 Reacting tetrahydrofuran compound with oxophilic electrophilic reagent to produce oxazoline compound |
| 01/30/2003 | US20030023091 For therapy and prophylaxis of peptic ulcers, gastro intestinal inflammatory diseases like duodenal/ gastric ulcer or gastritis or other gastro intestinal disorders |
| 01/30/2003 | US20030023088 To produce medicament for therapy and prophylaxis of cancer |
| 01/30/2003 | US20030023087 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| 01/30/2003 | US20030023085 For therapy and prophylaxis of condition or disorder mediated by a G-protein coupled receptor such as eating disorders, obesity, anxiety disorders and mood disorders |
| 01/30/2003 | US20030023084 For use in the oral hygiene |
| 01/30/2003 | US20030023079 For therapy of thrombosis in a mammal |
| 01/30/2003 | US20030023070 For diagnosis, prophylaxis and therapy; therapy of cancer |
| 01/30/2003 | US20030023061 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 01/30/2003 | US20030023047 For prevention of influenza virus binding to cells, therapy of schizophrenia and diagnosing chronic viral disease associated with development of cancer |
| 01/30/2003 | US20030023034 p27 (Kip1) -FKBP-12 protein complexes |
| 01/30/2003 | US20030023031 Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
| 01/30/2003 | US20030022944 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/30/2003 | US20030022942 Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion |
| 01/30/2003 | US20030022940 Novel pharmaceutical formulations of modafinil |
| 01/30/2003 | US20030022939 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical |
| 01/30/2003 | US20030022938 N-fatty acid-amino acid conjugates and therapeutic uses |
| 01/30/2003 | US20030022937 Therapeutic compositions |
| 01/30/2003 | US20030022935 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents |
| 01/30/2003 | US20030022934 For therapy and prophylaxis of pain and/or neurodegenerative disorders |
| 01/30/2003 | US20030022933 Administering to the patient a cathartic- inducing effective amount of halogenated bioactive lipid |
| 01/30/2003 | US20030022932 Identifying a bacterium that does not produce autoinducer-2; and contacting the bacterium with an amount of an autoinducer-2 effector that is sufficient to regulate the bacterium |
| 01/30/2003 | US20030022929 Method of using soluble epoxide hydrolase inhibitors |
| 01/30/2003 | US20030022928 Particle size distribution such that the median value of the volume mean diameter is between 450-700; blocking angiotensin II receptors, hypotensive agents and treating congestive heart failure and renal failure |
| 01/30/2003 | US20030022926 Method for treating neuropathic pain and pharmaceutical preparation therefor |
| 01/30/2003 | US20030022925 5-(dialkylamine)alkoxy)-1H-pyrazole derivatives |
| 01/30/2003 | US20030022924 Pyrazole derivative that mimics or agonizes hepatocyte growth factor/scatter factor; antiischemic agents |
| 01/30/2003 | US20030022923 Methods for treatment of sickle cell anemia |
| 01/30/2003 | US20030022922 Tablet, without excessive stickiness or tablet punch residue |
| 01/30/2003 | US20030022921 Stable pharmaceutical formulation comprising torsemide modification II |
| 01/30/2003 | US20030022918 (imidazoly-5-yl)methyl-2-quinolinone derivatives; antitumor agents |
| 01/30/2003 | US20030022915 Treating obsessive-compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, somatization disorder, specific social phobia, premenstrual dysphoric disorder, and other psychological disorders |
| 01/30/2003 | US20030022914 Nitric oxide synthase inhibitors |
| 01/30/2003 | US20030022912 Rapid-onset medicament for treatment of sexual dysfunction |
| 01/30/2003 | US20030022910 Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine |
| 01/30/2003 | US20030022909 Use of methylnaltrexone to treat immune suppression |
| 01/30/2003 | US20030022907 Anxiolytic agents and analgesics |
| 01/30/2003 | US20030022906 Use of pde v inhibitors |
| 01/30/2003 | US20030022904 Pyrazine compounds |
| 01/30/2003 | US20030022903 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| 01/30/2003 | US20030022902 Based upon 2-(N-(7-benzyl-9-methyl-1,5-dioxonan-2,6-dione-3-yl)amido)-3-hydroxy-4 -methoxypyridine; use as agricultural fungicide |
| 01/30/2003 | US20030022901 Serotonergic agents |
| 01/30/2003 | US20030022900 Compositions comprising alpha-1C specific compounds |
| 01/30/2003 | US20030022899 S-6-hydroxy-buspirone |
| 01/30/2003 | US20030022898 Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) |
| 01/30/2003 | US20030022897 Use of cox-2 inhibitors as gastroprokinetics |
| 01/30/2003 | US20030022896 Protein-tyrosine phosphatase (PTPase); treating diabetes or Syndrome X; (R)-2-(2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho(2,3-b)thiophen-4-yl) -phenoxy)-3-phenyl-propionic acid |
| 01/30/2003 | US20030022895 2-Amino-benzoxazinones for the treatment of viral infections |
| 01/30/2003 | US20030022894 Imidazotriazinone-containing compositions for nasal administration |
| 01/30/2003 | US20030022893 Hydroxamic and carboxylic acid derivatives |
| 01/30/2003 | US20030022891 Melanin-concentrating hormone (MCH); treating metabolic and eating disorders, such as hyperphagia, and diabetes; urea, thiourea and cyano-guanidine compounds of given formula |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022889 Administering a therapeutically effective of olanzapine or a salt or solvate thereof; treating amytrophic lateral sclerosis |
| 01/30/2003 | US20030022888 Use of mirtazapine for the treatment of sleep disorders |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022884 Heterocycle derivatives and drugs |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022882 Forming the 2-amino-2,4,4-trimethylpentane salt of clavulanic acid and converting that salt into a pharmaceutically acceptable salt of clavulanic acid, such as potassium clavulanate |
| 01/30/2003 | US20030022880 Soluble forms of amoxicillin and treatment of animals |
| 01/30/2003 | US20030022879 Via catheter comprising antimicrobial agent and second catheter for withdrawing fluid; for treating infection or neoplasm of cerebrospinal tissue |
| 01/30/2003 | US20030022878 Telomerase inhibitor |
| 01/30/2003 | US20030022877 Method of increasing testosterone and related steroid concentrations in women |
| 01/30/2003 | US20030022876 Sustained-release analgesic compounds |
| 01/30/2003 | US20030022875 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 01/30/2003 | US20030022874 New 17-halogenated 19-nor steroids, preparation process and intermediates, use as medicaments and the pharmaceutical compositions containing them |
| 01/30/2003 | US20030022873 Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis |
| 01/30/2003 | US20030022872 Possesses excellent binding property to vitamin D receptors; for treating diseases accompanied by abnormal calcium metabolism |
| 01/30/2003 | US20030022871 Inhibiting angiogenesis and shrinking tumors via administration of Id protein and HLH protein (helix-loop-helix); drug screening |
| 01/30/2003 | US20030022870 Methods of treating cardiac disorders |
| 01/30/2003 | US20030022868 Selective androgen receptor modulators and methods of use thereof |
| 01/30/2003 | US20030022867 Topical administration of amifostine and related compounds |
| 01/30/2003 | US20030022866 Analgesic inhibitor of isoforms of cyclic guanosine monophosphate (cGMP)-dependent protein kinase I alpha (PKGI alpha); drug screening |
| 01/30/2003 | US20030022865 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 01/30/2003 | US20030022863 Antiadhesive carbohydrates |
| 01/30/2003 | US20030022857 Mitogen-activated protein (MAP) kinase phosphatase (MKP) for use in metabolic disorders; gene expression; genetic engineering; diagnosis |
| 01/30/2003 | US20030022853 Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| 01/30/2003 | US20030022849 Nucleic acid vaccines for prevention of flavivirus infection |
| 01/30/2003 | US20030022848 Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression |
| 01/30/2003 | US20030022847 Administering antibiotics of quinolones, quinones, aminoglycosides or chloramphenicol to an individual under ischemic condition which lacks an adequate supply of oxygen and glucose |
| 01/30/2003 | US20030022845 Compositions comprising a mixture of bioflavonols |
| 01/30/2003 | US20030022843 Toluene sulfonamide - containing anti- tumor composition and method of use thereof |
| 01/30/2003 | US20030022842 Orally administering skin care agent comprising an ingestible carrier and natural-type N-acetylglucosamine obtainable by hydrolysis of chitin with an acid, an enzyme, or an acid and an enzyme |
| 01/30/2003 | US20030022836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 01/30/2003 | US20030022833 Inhibiting proliferation of a breast cancer cell which expresses a prolactin receptor, by exposing cell to a variant of human prolactin having a substitution of the glycine at position 129 |
| 01/30/2003 | US20030022830 Methods for enhancing functional recovery following central nervous system ischemia or trauma |
| 01/30/2003 | US20030022822 Novel compounds |
| 01/30/2003 | US20030022819 Administering to an animal an angiogenic amount of a hedgehog polypeptide or agonist to promote angiogenesis |
| 01/30/2003 | US20030022818 Formulations of tocopherols and methods of making and using them |
| 01/30/2003 | US20030022817 A protein hydrolysate to the preparation of a energy supplementation or metabolic nutrient, characterized in, that it is an animal or vegetable protein hydrolysate having a degree of hydrolysis of 1-50 |
| 01/30/2003 | US20030022814 Method for treating or preventing depression |